由于国内供应短缺,印度寻求对65种关键药品进行全球投标,豁免范围扩大到2027年。 India seeks global bids for 65 key medicines due to domestic supply shortages, with exemptions expanded until 2027.

印度正在对超过65种专利药品的全球招标进行评价,其中包括因国内生产不足而治疗癌症、糖尿病、心脏病和肥胖症的治疗。 India is evaluating global tenders for over 65 patented medicines, including treatments for cancer, diabetes, heart disease, and obesity, due to insufficient domestic production. 在紧急保健需要和供应缺口的驱动下,这项行动旨在改善中央机构,如武装部队医疗服务和雇员国家保险公司的准入。 The move, driven by urgent healthcare needs and supply gaps, aims to improve access for central agencies like the armed forces’ medical services and the Employees’ State Insurance Corporation. 对当地采购规则的豁免——通常将全球投标限制在200克郎以上的采购——正在扩大,到2027年3月为止,已有128种药品豁免。 Exemptions from local procurement rules—typically limiting global tenders to purchases over ₹200 crore—are being expanded, with 128 drugs already exempt until March 2027. 药剂部已邀请印度制造商在12月5日前反对评估国内生产的可行性。 The Department of Pharmaceuticals has invited objections from Indian manufacturers by December 5 to assess domestic production feasibility. 最终决定等待部际批准,预计将很快发出正式通知。 Final decisions await inter-ministerial approval, with a formal notification expected soon.